Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

NKp46+ lamina propria natural killer cells undergo metabolic reprogramming in a mouse experimental colitis model

Abstract

Objective

Both innate and adaptive immune system play important roles in the onset and progression of inflammatory bowel diseases (IBDs). However, the significance of natural killer (NK) cells for IBDs remains unclear. To understand the biology of colonic lamina propria natural killer (LPNK) cells in IBDs, we characterized LPNK cell metabolism in a murine acute colitis model.

Methods

C57BL/6J mice were fed with 3% dextran sulfate sodium to establish the acute colitis model. Colonic LPNK cells were isolated from mice through flow cytometry. The expression of metabolic genes in LPNK cells was analyzed by transcriptome sequencing and quantitative RT-PCR. Glucose uptake, Seahorse assay, and ATP assay were conducted to assess the metabolic status of LPNK cells. Phos-flow assay was performed to evaluate cell signaling pathways in LPNK cells. In vitro stimulation and cytotoxicity assay were conducted to measure the function of LPNK cells.

Results

In acute colitis, LPNK cells upregulated the expression of genes related to glycolysis and oxidative phosphorylation (oxphos), and enhanced glucose uptake capability. Intracellular ATP production, glycolysis and oxphos in LPNK cells were also promoted in acute colitis. mTORC1 signaling was essential for the metabolic reprogramming in LPNK cells in acute colitis. Although LPNK cells of diseased mice exhibited equivalent cytokine profile to normal LPNK cells upon stimulation with phorbol ester or IL-2, LPNK cells of diseased mice were more cytotoxic to target cells than normal LPNK cells.

Conclusions

LPNK cells undergo metabolic reprogramming which might be a response to upcoming microbial infection in acute colitis.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. 1.

    Silva FA, Rodrigues BL, Ayrizono ML, Leal RF. The Immunological basis of inflammatory bowel disease. Gastroenterol Res Pract. 2016;2016:2097274. https://doi.org/10.1155/2016/2097274.

  2. 2.

    Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3(7):521–33. https://doi.org/10.1038/nri1132.

  3. 3.

    Steinbach EC, Plevy SE. The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm Bowel Dis. 2014;20(1):166–75. https://doi.org/10.1097/MIB.0b013e3182a69dca.

  4. 4.

    Stagg AJ. Intestinal dendritic cells in health and gut inflammation. Front Immunol. 2018;9:2883. https://doi.org/10.3389/fimmu.2018.02883.

  5. 5.

    Imam T, Park S, Kaplan MH, Olson MR. Effector T helper cell subsets in inflammatory bowel diseases. Front Immunol. 2018;9:1212. https://doi.org/10.3389/fimmu.2018.01212.

  6. 6.

    Brandtzaeg P, Carlsen HS, Halstensen TS. The B-cell system in inflammatory bowel disease. Adv Exp Med Biol. 2006;579:149–67. https://doi.org/10.1007/0-387-33778-4_10.

  7. 7.

    Egawa S, Hiwatashi N. Natural killer cell activity in patients with inflammatory bowel disease. J Clin Lab Immunol. 1986;20(4):187–92.

  8. 8.

    Sanos SL, Bui VL, Mortha A, Oberle K, Heners C, Johner C, et al. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat Immunol. 2009;10(1):83–91. https://doi.org/10.1038/ni.1684.

  9. 9.

    Poggi A, Benelli R, Vene R, Costa D, Ferrari N, Tosetti F, et al. Human gut-associated natural killer cells in health and disease. Front Immunol. 2019;10:961. https://doi.org/10.3389/fimmu.2019.00961.

  10. 10.

    Yadav PK, Chen C, Liu Z. Potential role of NK cells in the pathogenesis of inflammatory bowel disease. J Biomed Biotechnol. 2011;2011:348530. https://doi.org/10.1155/2011/348530.

  11. 11.

    Steel AW, Mela CM, Lindsay JO, Gazzard BG, Goodier MR. Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. Aliment Pharmacol Ther. 2011;33(1):115–26. https://doi.org/10.1111/j.1365-2036.2010.04499.x.

  12. 12.

    Shimamoto M, Ueno Y, Tanaka S, Onitake T, Hanaoka R, Yoshioka K, et al. Selective decrease in colonic CD56(+) T and CD161(+) T cells in the inflamed mucosa of patients with ulcerative colitis. World J Gastroenterol. 2007;13(45):5995–6002. https://doi.org/10.3748/wjg.v13.45.5995.

  13. 13.

    Takayama T, Kamada N, Chinen H, Okamoto S, Kitazume MT, Chang J, et al. Imbalance of NKp44(+)NKp46(−) and NKp44(−)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology. 2010;139(3):882–92. https://doi.org/10.1053/j.gastro.2010.05.040(92.e1–3).

  14. 14.

    Sabatini DM. Twenty-five years of mTOR: uncovering the link from nutrients to growth. Proc Natl Acad Sci USA. 2017;114(45):11818–25. https://doi.org/10.1073/pnas.1716173114.

  15. 15.

    Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18(12):744–57. https://doi.org/10.1038/s41568-018-0074-8.

  16. 16.

    de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, et al. Inflammatory bowel disease: an overview of immune mechanisms and biological treatments. Mediators Inflamm. 2015;2015:493012. https://doi.org/10.1155/2015/493012.

  17. 17.

    Isidro RA, Appleyard CB. Colonic macrophage polarization in homeostasis, inflammation, and cancer. Am J Physiol Gastrointest Liver Physiol. 2016;311(1):G59–73. https://doi.org/10.1152/ajpgi.00123.2016.

  18. 18.

    Satoh-Takayama N, Vosshenrich CA, Lesjean-Pottier S, Sawa S, Lochner M, Rattis F, et al. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity. 2008;29(6):958–70. https://doi.org/10.1016/j.immuni.2008.11.001.

  19. 19.

    Van Acker A, Gronke K, Biswas A, Martens L, Saeys Y, Filtjens J, et al. A murine intestinal intraepithelial NKp46-negative innate lymphoid cell population characterized by Group 1 properties. Cell Rep. 2017;19(7):1431–43. https://doi.org/10.1016/j.celrep.2017.04.068.

  20. 20.

    Keppel MP, Saucier N, Mah AY, Vogel TP, Cooper MA. Activation-specific metabolic requirements for NK Cell IFN-gamma production. J Immunol. 2015;194(4):1954–62. https://doi.org/10.4049/jimmunol.1402099.

  21. 21.

    Marcais A, Cherfils-Vicini J, Viant C, Degouve S, Viel S, Fenis A, et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol. 2014;15(8):749–57. https://doi.org/10.1038/ni.2936.

  22. 22.

    Pfeifer C, Highton AJ, Peine S, Sauter J, Schmidt AH, Bunders MJ, et al. Natural killer cell education is associated with a distinct glycolytic profile. Front Immunol. 2018;9:3020. https://doi.org/10.3389/fimmu.2018.03020.

  23. 23.

    Keating SE, Zaiatz-Bittencourt V, Loftus RM, Keane C, Brennan K, Finlay DK, et al. Metabolic reprogramming supports IFN-gamma production by CD56bright NK cells. J Immunol. 2016;196(6):2552–600. https://doi.org/10.4049/jimmunol.1501783.

  24. 24.

    Donnelly RP, Loftus RM, Keating SE, Liou KT, Biron CA, Gardiner CM, et al. mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function. J Immunol. 2014;193(9):4477–84. https://doi.org/10.4049/jimmunol.1401558.

  25. 25.

    Viel S, Marcais A, Guimaraes FS, Loftus R, Rabilloud J, Grau M, et al. TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Science signaling. 2016;9(415):ra19. https://doi.org/10.1126/scisignal.aad1884.

  26. 26.

    Morita M, Gravel SP, Chenard V, Sikstrom K, Zheng L, Alain T, et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 2013;18(5):698–711. https://doi.org/10.1016/j.cmet.2013.10.001.

  27. 27.

    Bernardini G, Sciume G, Santoni A. Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow. Front Immunol. 2013;4:12. https://doi.org/10.3389/fimmu.2013.00012.

  28. 28.

    Mocellin S, Panelli M, Wang E, Rossi CR, Pilati P, Nitti D, et al. IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immunity. 2004;5(8):621–630. https://doi.org/10.1038/sj.gene.6364135.

Download references

Acknowledgements

This research was supported by Wuhan Clinical Research Foundation [Grant# WX14C22].

Author information

Correspondence to Chao Ke.

Ethics declarations

Conflicts of interest

The authors declare no conflict of interest with regard to the publication of this paper.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Responsible Editor: John Di Battista.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 773 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhou, H., Xie, X., Jiang, B. et al. NKp46+ lamina propria natural killer cells undergo metabolic reprogramming in a mouse experimental colitis model. Inflamm. Res. (2020). https://doi.org/10.1007/s00011-020-01324-2

Download citation

Keywords

  • Inflammatory bowel diseases
  • Natural killer cells
  • Metabolism
  • Glycolysis
  • Oxidative phosphorylation
  • mTORC1